Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- DPJ Lawmakers Call for Withdrawal of Proposal to Unify Basic Dispensing Fees
July 11, 2011
- DPJ's Diet Members Adopt Opinion Paper Calling for Deregulating Online Sales of OTC Drugs
July 11, 2011
- Sogo Medical to Increase Number of Mentaio Pharmacies to 20 in 3 Years
July 11, 2011
- Ono, Evotec Succeed in Discovering Lead Compounds in Iron Channel Drug Discovery
July 11, 2011
- Eisai to Enhance Liver Disease Franchise in Asia/Pacific Region
July 11, 2011
- Mediceo to Use Its MR-Certified MSs to Promote Orphan Drugs
July 11, 2011
- Sanofi-aventis, Tohoku Univ. Sign Comprehensive Agreement for Life Science Research
July 11, 2011
- Pfizer Remains Top Global Drug Maker; Mergers Shake up Ranking
July 11, 2011
- Kyowa Hakko Kirin Starts Domestic PIII Trial for KW-3357
July 11, 2011
- 24 APIs/34 Products Approved Following New Procedures
July 11, 2011
- AnGes MG Obtains Substance Patent for Novel Peptide AG-30 in Japan
July 11, 2011
- Approvals for 3 Dasen-Like Drugs to Be Withdrawn
July 11, 2011
- Sawai May Embark on Follow-on Antibody Drugs in Mid-2010s: President Sawai
July 11, 2011
- METI's Council Proposes Review of Patients' Drug Copayments
July 11, 2011
- AnGes MG Obtains Patent on HVJ-E for Cancer
July 4, 2011
- R&I Upgrades Kaken's Rating from “Stable”to “Positive”
July 4, 2011
- Takeda Applies for SGN-35 in Europe
July 4, 2011
- Current Users to Be Permitted to Rely on Telemarketing to Buy Reclassified Class 2 OTC Drugs
July 4, 2011
- R&I Keeps AA- Rating for Eisai
July 4, 2011
- Merck Serono Stops Global Approval Process for Cladribine
July 4, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…